XTNT
Xtant Medical Holdings, Inc.
XTNT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
XTNT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
XTNT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
XTNT PE Valuation
XTNT has no meaningful PE right now: it lost money over the past year.
XTNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect XTNT's losses to shrink, with revenue growing.
XTNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.08 | -$0.04 |
| Q1 2026 | $0.01 | +$0.10 |
| Q4 2025 | $0.03 | +$0.15 |
| Q3 2025 | $0.01 | +$0.13 |
| Q2 2025 | -$0.04 | -$0.03 |
| Q1 2025 | -$0.09 | -$0.09 |
| Q4 2024 | -$0.12 | -1300% |
| Q3 2024 | -$0.12 | -700% |
XTNT is still losing money, but far less than before: $0.08 per share over the past year, against $5.15 at its worst in late 2019.
XTNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23M | -35% |
| Q1 2026 | $20.9M | -37% |
| Q4 2025 | $32.4M | +2.7% |
| Q3 2025 | $33.3M | +19% |
| Q2 2025 | $35.4M | +18% |
| Q1 2025 | $32.9M | +18% |
| Q4 2024 | $31.5M | +12% |
| Q3 2024 | $27.9M | +12% |
XTNT's revenue has slid since its 2025 peak: $23M last quarter, down 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -40% | -53 points |
| Q1 2026 | -14% | -17 points |
| Q4 2025 | -2.9% | +3 points |
| Q3 2025 | 7.6% | +21 points |
| Q2 2025 | 13% | +23 points |
| Q1 2025 | 3.2% | +16 points |
| Q4 2024 | -6% | +7.6 points |
| Q3 2024 | -14% | 0 points |
XTNT's operating margin was −40% last quarter, down 53 points from the same quarter a year ago, near the bottom of its range since 2019.
XTNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | -930% |
| Q1 2026 | -$2.3M | -2753% |
| Q4 2025 | $5M | +$5M |
| Q3 2025 | $4.2M | +$8M |
| Q2 2025 | $910K | +$6.6M |
| Q1 2025 | $87K | +$6.6M |
| Q4 2024 | -$7K | +$1.3M |
| Q3 2024 | -$3.8M | +$235K |
XTNT has burned cash in most quarters: −$696,000 over the past year, against −$3M the year before.
XTNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +200K shares |
| 1 year | -5.6% | -8.3M shares |
| 3 years | +29% | +31.4M shares |
| 5 years | +62% | +53.6M shares |
| Available history | +966% | +127M shares |
XTNT has 140M diluted shares, down 5.6% from a year ago.
XTNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 3.4x | Elevated |
| Q2 2021 | -4.0x | Net Cash |
| Q1 2021 | -0.9x | Net Cash |
| Q4 2020 | 10.9x | High |
| Q3 2020 | 66.6x | High |
XTNT has more cash than debt.
XTNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 5.3 | Oversold |
XTNT's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
XTNT PE vs Healthcare Sector
| Metric | XTNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTNT has no meaningful PE right now: it lost money over the past year.
XTNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 9.7% below |
| 20 week MA | $0.35 | 20% below |
| 50 week MA | $0.49 | 43% below |
| 100 week MA | $0.54 | 48% below |
| 200 week MA | $0.69 | 59% below |
XTNT is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
XTNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.67 | $1.20 | -28% |
| 2021 | $1.20 | $0.66 | -45% |
| 2022 | $0.66 | $0.66 | 0% |
| 2023 | $0.66 | $1.13 | +71% |
| 2024 | $1.13 | $0.46 | -59% |
| 2025 | $0.46 | $0.78 | +70% |
| 2026 YTD | $0.78 | $0.28 | -64% |
XTNT has finished lower in four of the last six years. It's down 64% so far in 2026.